|
| 游离肿瘤DNA在肝细胞中的研究进展 |
| The Research Progress of Circulating Tumor DNA in Hepatocellular Carcinoma |
| 投稿时间：2024-11-11 修订日期：2025-02-12 |
| DOI： |
| 中文关键词: 循环肿瘤DNA 肝细胞癌 诊断 治疗 复发和预后 |
| 英文关键词: Circulating tumor DNA liver cancer biomarker |
| 基金项目:云南省科技厅重大科技专项计划项目（课题编号：202301AY070001-112）；云南省临床药学中心建设项目(昆明市第一人民医院2022年-2025年)；昆明市卫生科技人才培养项目（编号：2022-SW（带头）-32） |
|
| 摘要点击次数: 52 |
| 全文下载次数: 0 |
| 中文摘要: |
| 肝细胞癌（HCC）是全球范围内常见且致死率较高的恶性肿瘤之一。游离肿瘤DNA（ctDNA）来源于肿瘤细胞的凋亡或坏死，其在血液中的定量分析、基因突变检测以及甲基化分析，对于HCC的早期诊断、疗效评估、复发及预后具有重要价值。ctDNA检测因其无创、快速、实时且具有较高特异性和灵敏度的优势，已逐渐成为癌症研究中的一个重要热点。本文综述了ctDNA在HCC早期诊断、预后评估、治疗决策及动态监测方面的最新研究进展，旨在为临床应用提供参考与指导。 |
| 英文摘要: |
| Circulating tumor DNA (ctDNA) has emerged as a transformative biomarker with substantial potential for the early diagnosis, prognostic stratification, and therapeutic monitoring of hepatocellular carcinoma (HCC). Extensive research indicates a significant correlation between ctDNA profiles and the molecular mechanisms underpinning HCC pathogenesis and progression. The characterization of ctDNA allows for improved precision in tumor staging and facilitates the development of individualized therapeutic strategies. In comparison to conventional tissue biopsies, ctDNA analysis offers notable advantages, including its non-invasive nature, rapid turnaround times, and capacity for longitudinal monitoring, thereby enhancing patient accessibility to diagnostic assessments. Additionally, ctDNA serves as a valuable tool for evaluating treatment response and predicting clinical outcomes. However, the clinical application of ctDNA is accompanied by challenges, including the need for harmonized detection methodologies and the influence of tumor heterogeneity on ctDNA shedding and concentration. This review critically examines the clinical implications of ctDNA in HCC, offering key insights for advancing personalized medicine and optimizing therapeutic interventions in affected populations. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
